Long-term risk of all-cause mortality in live kidney donors: a matched cohort study

Eunjeong Kang¹, Sehoon Park², Jina Park³, Yaerim Kim⁴, Minsu Park⁵, Kwangsoo Kim⁶, Hyo Jeong Kim⁷, Miyeun Han⁸, Jang-Hee Cho⁹, Jung Pyo Lee¹⁰, Sik Lee¹¹, Soo Wan Kim¹², Sang Min Park¹³, Dong-Wan Chae¹⁴, Ho Jun Chin¹⁴, Yong Chul Kim¹⁵, Yon Su Kim¹⁵, Insun Choi⁷, Hajeong Lee¹⁵

Background: Long-term outcomes of live kidney donors remain controversial, although this information is crucial for selecting potential donors. Thus, this study compared the long-term risk of all-cause mortality between live kidney donors and healthy control.

Methods: We performed a retrospective cohort study including donors from seven tertiary hospitals in South Korea. Persons who underwent voluntary health screening were included as controls. We created a matched control group considering age, sex, era, body mass index, baseline hypertension, diabetes, estimated glomerular filtration rate, and dipstick albuminuria. The study outcome was progression to end-stage kidney disease (ESKD), and all-cause mortality as identified in the linked claims database.

Results: We screened 1,878 kidney donors and 78,115 health screening examinees from 2003 to 2016. After matching, 1,701 persons remained in each group. The median age of the matched study subjects was 44 years, and 46.6% were male. Among the study subjects, 2.7% and 16.6% had underlying diabetes and hypertension, respectively. There were no ESKD events in the matched donor and control groups. There were 24 (1.4%) and 12 mortality cases (0.7%) in the matched donor and control groups, respectively. In the age-sex adjusted model, the risk for all-cause mortality was significantly higher in the donor group than in the control group. However, the significance was not retained after socioeconomic status was included as a covariate (adjusted hazard ratio, 1.82; 95% confidence interval, 0.87–3.80).

Conclusion: All-cause mortality was similar in live kidney donors and matched non-donor healthy controls with similar health status and socioeconomic status in the Korean population.

Keywords: End-stage kidney disease, Living donors, Mortality, Risk assessment, Prognosis

Introduction

Kidney transplantation from living donors is the best treatment option for end-stage kidney disease (ESKD). Even considering graft and patient survival, living donor kidney transplantation has shown superior outcomes for recipients compared to kidney transplantation from deceased donors [1]. However, living donor kidney transplantation requires...
meticulous considerations regarding various medical, ethical, and moral issues. Considering the complex circumstances surrounding kidney transplantation, living donors might not consider adequately the long-term medical risks of nephrectomy. Physicians managing live kidney donors should recognize these risks and help donors to make reasonable decisions based on scientific evidence.

Long-term safety issues regarding kidney function recovery, quality of life, and the risk of progression to ESKD and all-cause mortality remain controversial. Studies from the United States [2], Canada [3], and South Korea [4] using matched non-donor comparators demonstrated that live kidney donors had similar mortality risks to individuals with a similar baseline health status. However, a Norwegian study reported higher mortality risk for live kidney donors compared with matched controls. A recent meta-analysis showed the absence of a definite increase in the risk of mortality [5]. The estimates of the long-term effects of donor nephrectomy regarding ESKD increased by 8 to 11 times in recent data from a large cohort [1,6,7].

These controversial results are attributed partially to incomplete follow-up medical records for live kidney donors, leading to difficulties in ascertaining long-term medical complications [8]. In addition, selecting individuals who have similar health statuses to donors is crucial for valid comparisons. Pre-existing studies used various comparators, including the general population [5,9–12], non-donating siblings [13,14], or healthy volunteers [5,15,16]. Living donors are selected only after careful evaluation that confirms a health status that satisfies the donor criteria, indicating that living donors are healthier than the general population [4]. Since they are highly likely to share the inheritance of kidney disease, hypertension, and diabetes, the effect of donor nephrectomy alone might not be identified when comparing non-sibling donors [13,17]. Moreover, most of the above studies adopted controls from population-based administrative data or self-questionnaires instead of objective medical records. It is important to establish healthy non-donor comparators to determine the risks of kidney donation.

Recently, we showed that the mortality risk of Korean live kidney donors did not exceed that of non-donor comparators with similar health status [4]. This previous study was limited by its single-center design; thus, in the current study, we aimed to clarify the long-term risk of all-cause mortality in live kidney donors and healthy non-donor controls from seven national university-affiliated medical centers in South Korea. We linked the medical records of the donors and controls to the National Health Insurance Service (NHIS) database of South Korea to include the nationwide occurrence of mortality.

**Methods**

**Ethical approval**

This study was approved by the Institutional Review Board (IRB) of each participating clinical center as follows: Seoul National University Hospital (No. H-1903-116-1019), Seoul National University Bundang Hospital (No. B-1905/540-402), Seoul National Hospital Boramae Medical Center (No. 20190422/30-2019-28/053), Jeonbuk National University Hospital (No. CUH 2019-05-068), Chonnam National University Hospital (No. CNUH-2019-163), Kyungpook National University Hospital (No. 2019-04-014-001), and Pusan National University Hospital (No. H-1905-018-079). The IRBs waived the requirement for informed consent as the study analyzed an anonymous database provided by the NHIS of South Korea. The study was consistent with the principles of the Declaration of Istanbul.

**Study setting**

This study was a retrospective multicenter study performed in seven national university-affiliated hospitals in South Korea. The study included living kidney transplantation donors and a control group that included people who voluntarily received general health screenings. Donors received routine cardiac screenings (e.g., electrocardiogram) before their kidney donations. In addition to the basic analysis, further matching was performed to secure compatibility between the two groups. Baseline information was collected by electronic medical record review in each center to provide more detailed information compared to using the claims database. Further, outcome details were collected from the national claims database of the NHIS of Korea, which generally provides health insurance for all Koreans. The outcome details included both intra-center outcomes and all the outcomes that occurred within South Korea.
Study population

The donor group included live kidney donors from 2003 to 2016. The matched healthy non-donor control group included subjects who received general health screenings in one of the hospitals during the same period [4,18,19]. As the control group included individuals with various medical conditions, we initially excluded those who overlapped with the donor group and who had an estimated glomerular filtration rate (eGFR) less than 50 mL/min/1.73 m². We additionally excluded the study subjects, both donors and controls, according to data availability, including those without identifiable follow-up data in the claims database and those without information regarding important covariates such as age, sex, diabetes mellitus, hypertension, body mass index, eGFR, or dipstick urine results.

Ascertainment of outcomes

The primary study outcome was all-cause mortality. The NHIS database includes nationwide mortality information through issued death certificates. Mortality outcomes were identified through December 31, 2018.

Data collection

The baseline covariates were collected from electronic medical records and comprised age, sex, body mass index, history of diabetes mellitus, hypertension, serum creatinine level, eGFR based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) method [20,21], dipstick albuminuria results, baseline systolic and diastolic blood pressures, and levels of plasma hemoglobin and serum uric acid. In addition, we obtained information on economic status and area of residence from the NHIS system. We collected events regarding progression to ESKD through claims information, which issues specific codes for ESKD, as the status receives additional insurance coverage in Korea.

Matching process

In addition to the basic analysis, we additionally conducted an analysis with a matched dataset. We used direct matching based on the following variables: age (allowing intervals of ±5 years and ≥60 years or not), sex, era (allowing intervals of ±3 years), body mass index (≥25 kg/m² or not according to the Korean obesity guidelines [22]), presence of prior diabetes mellitus and hypertension, eGFR (allowing intervals of ±10 mL/min/1.73 m²), and presence of dipstick albuminuria (negative/trace or ≥1+). Subjects without a match were excluded from the analysis of the matched datasets. Although socioeconomic status was considered initially as a possible matching variable, because of the very large differences in the distribution of status, the variable instead was included as a covariate in the multivariable model. To assess the potential bias resulting from the matching process, we performed bootstrap matching 1,000 times and investigated the distribution of p-values and effect sizes in the multivariable-adjusted model.

Statistical analysis

Categorical variables are presented as number (%) and continuous variables are presented as median (interquartile range [IQR]). Univariable, age- and sex-adjusted, and multivariable Cox regression models were constructed. The multivariable model included baseline age, sex, time period (2003–2008, 2009–2012, 2013–2016), history of diabetes mellitus or hypertension, body mass index (≥25 kg/m² or not), dipstick albuminuria (negative/trace or ≥1+), baseline eGFR, economic status, and region of residence. The results before and after the matching process are presented. Additional analyses to identify the risk factors for all-cause mortality were conducted, and the analyses included all the donors from 2003 to 2016. In the analyses, all collected variables were investigated for a significant association with progression to ESKD or all-cause mortality. Age (≥60 years or less) and eGFR (≥80 mL/min/1.73 m² or less) were recategorized according to the suggested definition for the
extended criteria donor. In the risk factor analysis, univariate and multivariable logistic regression analyses were employed, and in the multivariable model, the backward-elimination method was used to identify significant risk factors for adverse study outcomes. There was no missing information in the regression models. All statistical analyses were performed using R version 3.6.2 (R Foundation for Statistical Computing, Vienna, Austria), and two-sided p-values of <0.05 were considered to indicate statistical significance.

Results

Study population

We collected 3,456 donor cases from electronic medical record reviews in the study hospitals (Fig. 1). Among them, 1,578 cases underwent their donations at times other than 2003 to 2016 and thus were excluded. Among the remaining 1,878 donors and 78,115 healthy controls from 2003 to 2016, 1,751 donors and 71,903 healthy controls were included in this study after applying the exclusion criteria. As we could not find exactly matched controls for 50 of the donors, the matched data set included 1,701 donors and the same number of healthy controls.

Characteristics of the study population

The baseline characteristics before and after the matching process involving all the subjects are presented in Table 1 and Supplementary Table 1 (available online). Before matching, the donors had a relatively lower median age, in addition to lower proportions of male sex, obesity, diabetes mellitus, hypertension, and dipstick albuminuria. They also had higher eGFR values. Regarding economic status or region of residence, the controls had higher wealth percentiles and lived more in urban areas. After matching, the imbalance in the matched variables was no longer observed; however, the matched controls had higher wealth percentiles and higher proportions of urban residence. The prevalence of hypertension was 16.6 % and that of diabetes was 2.7%. There were 1.6% of matched donors/controls who had dipstick albuminuria.

Before and after matching, no donors progressed to ESKD in the study population. In contrast, 128 healthy controls progressed to ESKD before matching, but none of the controls had ESKD events after matching.

Risks of all-cause mortality

Before matching, we identified 24 mortality events (incidence rate, 1.64/1,000 person-years; average age at death, 55.1 ± 15.6 years old; average time from index date to death, 6.6 ± 4.5 years) in the donors and 2,533 mortality events (incidence rate, 3.04/1,000 person-years; average age at death, 62.8 ± 11.6 years old; average time from index date to death, 7.8 ± 4.1 years) in the healthy controls during the median follow-up duration of 12.5 years (IQR, 9.4–14.4 years) (Table 2). In the univariable model, the donors had a lower risk of all-cause mortality than the controls, but the reverse was noted in the age-sex adjusted model. However, with additional consideration for economic status or regions of residence, the difference in mortality risk was nonsignificant. After matching, while the matched donors had 24 mortality events (incidence rate, 1.68/1,000 person-years; average age at death, 48.5 ± 14.7 years old; average time from index date to death, 6.6 ± 4.5 years) during the median follow-up duration of 7.7 years (IQR, 4.8–11.8 years), the matched control group had 12 death cases (incidence rate, 0.83/1,000 person-years; average age at death, 49.8 ± 14.2 years old; average time from index date to death, 6.1 ± 4.4 years) during the median follow-up duration of 7.8 years (IQR, 5.0–12.0 years). The survival analysis showed that the difference in risk of mortality was nonsignificant after consideration for region of residence and economic status, similar to the results before the matching process. When we performed bootstrapping for matching (Table 3), the most (99.4%) adjusted multivariable model yielded nonsignificant results.

Risk factors for all-cause mortality in living donors

Regarding risk factors, among the 1,751 donors, including the total cases before matching, from 2003 to 2016, age ≥ 60 years was a risk factor for all-cause mortality in the univariable analysis, and it was the only variable that remained after the backward-elimination method (Table 4). Other variables were not significantly associated with the risk of mortality in the donors.
Discussion

In this multicenter observational study in South Korea, we identified that the prognosis of live kidney donors was comparable to that of healthy individuals when socioeconomic status was considered. This study suggests that, in this Korean population, the survival of living donors is generally similar to that of healthy individuals.

Because living donors donate kidneys despite perioperative risks and surgical complications, it is essential to provide accurate information regarding the long-term risks and safety of this procedure. However, most live kidney donor studies have been conducted in the Western population [1-3,6,23,24], with a lack of data for Asians. As the proportion of live kidney transplantations is not only substantial but also gradually increasing in South Korea [25], this study...
is important to clarify the long-term mortality of living donors, especially in the Korean population. We compared long-term all-cause mortality outcomes of live kidney donors using a well-characterized non-donor control group with similar health status and found it comparable all-cause mortality in the two groups. This was shown repeatedly in the sensitivity analysis using the bootstrap method.

There are some difficulties in conducting studies for live kidney donors. First, because live kidney donors are determined after detailed health screening tests, it is important to select a comparative group with similar health status. Additionally, because living donors are healthy individuals, long-term follow-up is required to observe notable clinical outcomes such as ESKD and mortality. Although several studies have compared live kidney donors with matched comparison groups, some studies [2–4] have reported that donors had similar mortality risks compared to matched controls, but a large-scale Norwegian study [1] showed a higher mortality risk for donors. Thus, there are some controversies to date regarding the long-term risks of live kidney donors (Table 5).

In a single-center study in South Korea by Kim et al. [4], which was the first report to include long-term mortality data in an Asian population, the mean follow-up duration was 12 years, and the risks of all-cause mortality were similar between live kidney donors and the matched donors.

### Table 1. Baseline characteristics

| Characteristic | Donor (n = 1,701) | Control (n = 1,701) | p-value |
|---------------|------------------|---------------------|---------|
| **Matched variable** | | | |
| Age (yr) | 44.0 (35.0–52.0) | 44.0 (36.0–52.0) | 0.64 |
| ≥60 | 107 (6.3) | 107 (6.3) | >0.99 |
| Sex | | | >0.99 |
| Male | 792 (46.6) | 792 (46.6) | |
| Female | 909 (53.4) | 909 (53.4) | |
| Body mass index (kg/m²) | 23.4 (21.6–25.4) | 23.1 (21.0–25.4) | 0.002 |
| ≥25 | 512 (30.1) | 512 (30.1) | >0.99 |
| Underlying disease | | | |
| Diabetes mellitus | 46 (2.7) | 46 (2.7) | >0.99 |
| Hypertension | 283 (16.6) | 283 (16.6) | >0.99 |
| Creatinine (mg/dL) | 0.8 (0.7–0.9) | 0.8 (0.7–0.9) | 0.51 |
| eGFRa (mL/min/1.73 m²) | 100.3 (89.0–108.9) | 100.1 (89.1–108.5) | 0.46 |
| Dipstick albuminuria (≥1+) | 28 (1.6) | 28 (1.6) | >0.99 |
| **Unmatched variable** | | | |
| Systolic blood pressure (mmHg) | 120.0 (110.0–130.0) | 118.0 (109.0–129.0) | 0.39 |
| Diastolic blood pressure (mmHg) | 73.0 (67.0–80.0) | 72.0 (65.0–79.0) | 0.002 |
| Hemoglobin (g/dL) | 13.7 (12.7–15.0) | 14.2 (13.1–15.4) | <0.001 |
| Uric acid (mg/dL) | 4.8 (4.0–5.9) | 5.1 (4.2–6.2) | <0.001 |
| Wealth percentile | | | <0.001 |
| 0 (aided) | 68 (4.0) | 2 (0.1) | |
| 1st–25th | 332 (19.5) | 174 (10.2) | |
| 26th–50th | 378 (22.2) | 198 (11.6) | |
| 51st–75th | 426 (25.0) | 369 (21.7) | |
| 76th–100th | 497 (29.2) | 958 (56.3) | |
| Place of residence | | | <0.001 |
| Rural | 588 (34.6) | 269 (15.8) | |
| Urban | 1,113 (65.4) | 1,432 (84.2) | |

Data are expressed as median (interquartile range) or number (%).

eGFR, estimated glomerular filtration rate.

aDirectly matched variables.
comparison group. However, their study was limited by its single-center nature, the enrollment of 7.7% of patients with a follow-up period of <1 year, and evaluation of all-cause mortality alone without considering ESKD. Although our study used a similar comparator group as this previous study, there are several differences between the two studies. Our current study was a multicenter study that included seven national universities across South Korea and acquired ample detailed clinical outcome data by linking electrical medical records and administrative data from NHIS. The current study, which complements the previous study, showed that the long-term rates of all-cause mortality of donors and non-donors were similar, particularly when the baseline socioeconomic status was considered. Moreover, it is noteworthy that the absolute numbers of ESKD and mortality events of live kidney donors are small in South Korea, indicating that live kidney donation is a safe procedure in this population.

Considering that more diabetic and hypertensive patients were included than in other studies, the absolute outcome risk in this Korean population might be low (Table 5). The exact mechanism of this phenomenon is unknown, but Asians are considered to have lower metabolic risks for adverse health outcomes such as obesity [26] and diabetes mellitus [27,28] compared to Western populations.

An important finding in the present study is that socioeconomic status was the major confounding factor for mortality outcomes [29,30]. Differences in socioeconomic status and area of residence were observed between the matched donors and the non-donor healthy controls. Because these differences were notable, these two variables could not be included as matching variables. Because the matched non-donor healthy controls included in this study self-funded their voluntary medical check-ups, it is likely that their socioeconomic status and interest in health were higher than those of the donors. Thus, we conducted an analysis including socioeconomic status and region of residence as covariates. The significant difference in mortality was not observed in the multivariable analysis when both variables were included as covariates. This means that socioeconomic status might be a major confounder regarding the risk of long-term donor mortality, which is evident in the general population of those with chronic kidney disease [31,32]. Further studies are needed to clarify the impact of socioeconomic status on the long-term outcomes of kidney donors owing to the limited evidence regarding this subject. Moreover, our study suggests the importance of considering socioeconomic status when comparing the prognoses of living donors to those of healthy individuals.

There are some limitations to this study. First, the hospitals included in this study might have different donor management programs and exclusion criteria according to

### Table 2. Risk of all-cause mortality in the donors and controls from 2003 to 2016

| Matching and group | Outcome/subjects (n) | Univariable model | Age-sex adjusted model | Multivariable model* |
|-------------------|----------------------|-------------------|------------------------|----------------------|
|                   | HR (95% CI) | p-value | Adjusted HR (95% CI) | p-value | Adjusted HR (95% CI) | p-value |
| **Before matching** |           |         |                       |         |                       |         |
| Donor             | 24/1,751  | 0.60 (0.40–0.90) | 0.01              | 1.68 (1.12–2.52) | 0.01              | 1.41 (0.94–2.13) | 0.10 |
| Control           | 2,533/71,903 | Reference |                       | Reference |                       | Reference |
| **After matching** |           |         |                       |         |                       |         |
| Donor             | 24/1,701  | 2.01 (1.01–4.03) | 0.05              | 2.00 (1.00–4.00) | 0.05              | 1.82 (0.87–3.80) | 0.11 |
| Control           | 12/1,701  | Reference |                       | Reference |                       | Reference |

CI, confidence interval; HR, hazard ratio.

*Adjusted for age, sex, era, history of diabetes mellitus, hypertension, body mass index, dipstick albuminuria, baseline estimated glomerular filtration rate, socioeconomic status, and region of residence (urban or rural).

### Table 3. Results bootstrapped for 1,000 iterations of the matching process with the matched population included from 2003 to 2016

| Variable             | No. of p < 0.05 | p-value (IQR) | HR (IQR) | No. of HR > 1 | No. of HR > 2 |
|----------------------|-----------------|---------------|----------|---------------|---------------|
| Univariable model    | 526             | 0.05 (0.03–0.10) | 2.01 (1.73–2.20) | 1,000 | 524 |
| Age- and sex-adjusted model | 424         | 0.05 (0.03–0.11) | 2.00 (1.72–2.18) | 1,000 | 371 |
| Multivariable model  | 60              | 0.13 (0.08–0.20) | 1.76 (1.59–1.94) | 1,000 | 181 |

HR, hazard ratio; IQR, interquartile range.
Table 4. Risk factors for all-cause mortality in all donors during 2003 to 2016

| Variable                        | No. of donors | Event | Univariable model | Multivariable model<sup>a</sup> |
|--------------------------------|---------------|-------|-------------------|----------------------------------|
|                                |               |       | HR (95% CI)       | p-value                          | Adjusted HR (95% CI) | p-value |
|                                |               |       | Reference         |                                  | Reference            |         |
| **Age (yr)**                   |               |       |                   |                                  |                     |
| <60                            | 1,644         | 19    |                   |                                  |                     |
| ≥60                            | 107           | 5     | 6.05 (2.23–16.36) | <0.001                           | 6.50 (2.39–17.68)   | <0.001  |
| **Sex**                        |               |       |                   |                                  |                     |
| Male                           | 829           | 12    | Reference         |                                  |                     |
| Female                         | 922           | 12    | 0.96 (0.43–2.14)  | 0.92                             |                     |
| **Body mass index (kg/m<sup>2</sup>)** |         |       |                   |                                  |                     |
| <25                            | 1,220         | 18    | Reference         |                                  |                     |
| ≥25                            | 531           | 6     | 0.85 (0.34–2.13)  | 0.72                             |                     |
| **eGFR (mL/min/1.73 m<sup>2</sup>)** |         |       |                   |                                  |                     |
| <80                            | 174           | 4     | Reference         |                                  |                     |
| ≥80                            | 1,577         | 20    | 0.74 (0.25–2.18)  | 0.59                             |                     |
| **Dipstick albuminuria**       |               |       |                   |                                  |                     |
| Trace or –                     | 1,722         | 24    | Reference         |                                  |                     |
| ≥1+                            | 29            | 0     | NA                |                                  |                     |
| **Diabetes mellitus**          |               |       |                   |                                  |                     |
| No                             | 1,702         | 24    | Reference         |                                  |                     |
| Yes                            | 49            | 0     | NA                |                                  |                     |
| **Hypertension**               |               |       |                   |                                  |                     |
| No                             | 1,458         | 20    | Reference         |                                  |                     |
| Yes                            | 293           | 4     | 1.09 (0.37–3.19)  | 0.88                             |                     |
| **Wealth percentile**          |               |       |                   |                                  |                     |
| 0 (aided)                      | 68            | 1     | Reference         |                                  |                     |
| 1st–25th                       | 346           | 5     | 1.33 (0.16–11.43) | 0.79                             |                     |
| 26th–50th                      | 390           | 6     | 1.38 (0.17–11.46) | 0.77                             |                     |
| 51st–75th                      | 438           | 5     | 1.00 (0.12–8.55)  | >0.99                            |                     |
| 76th–100th                     | 509           | 7     | 1.19 (0.15–9.66)  | 0.87                             |                     |
| **Place of residence**         |               |       |                   |                                  |                     |
| Rural                          | 610           | 9     | Reference         |                                  |                     |
| Urban                          | 1,141         | 15    | 0.91 (0.40–2.08)  | 0.82                             |                     |
| **Relation**                   |               |       |                   |                                  |                     |
| Parent-sibling                 | 669           | 10    | Reference         |                                  |                     |
| Brothers, sisters, or other relatives | 546   | 9     | 0.86 (0.35–2.11)  | 0.74                             |                     |
| Unrelated                      | 533           | 5     | 0.64 (0.22–1.86)  | 0.41                             |                     |
| **Operation method**           |               |       |                   |                                  |                     |
| Laparoscopy                    | 1,232         | 17    | Reference         |                                  |                     |
| Open                           | 320           | 4     | 0.40 (0.13–1.27)  | 0.12                             |                     |
| **Donated kidney side**        |               |       |                   |                                  |                     |
| Left                           | 1,616         | 21    | Reference         |                                  |                     |
| Right                          | 131           | 2     | 0.93 (0.22–3.99)  | 0.93                             |                     |

The effect sizes in the multivariable model were different from those in the univariable model, although a single variable (age ≥ 60 years) remained after backward elimination because the multivariable analysis was performed with 1,744 individuals due to missing data for the considered variables. CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; NA, not applicable.

<sup>a</sup>By backward-elimination method.
| Variable | Current study | Mjøen et al. [1] (2014) | Muzaale et al. [6] (2014) | Segev et al. [2] (2010) | Kim et al. [4] (2020) |
|----------|---------------|------------------------|--------------------------|------------------------|---------------------|
| No. of donors | 1,701          | 1,901                  | 96,217                   | 80,347                 | 1,292               |
| Control   | Subjects who received general health screenings voluntarily | HUNT 1 including BP ≤ 140/90 mmHg, BMI ≤ 30 kg/m², and those who rated their own health as 'good' or 'excellent' | NHANES III after excluding those with contraindications to kidney donation | NHANES III after excluding those with contraindications to kidney donation | Subjects who received general health screenings voluntarily |
| Age (yr) | Median: 44.0 (35–51) | Mean: 46.0 ± 11.5 | 40.2 ± 11.1 | 18–39 (49.2%) | 40.7 ± 11.1 |
| Male sex | 46.6%          | 41%                    | 41%                      | 41.5%                  | 47.7%               |
| Race     | Asian (100%)   | NA                     | White (74.6%)            | White (73.1%)          | Asian (100%)        |
|          |                |                        | Black (12.9%)            | Black (13.1%)          |                    |
|          |                |                        | Hispanic (12.5%)         | Hispanic (12.3%)       |                    |
|          |                |                        | Others (1.6%)            |                        |                    |
| eGFR (mL/min/1.73m²) | Median: 100.3 | Mean: 104.7 | Means: 100.7 (donor), 86.4 (control) | 117 mL/min (creatinine clearance) | Mean: 96.0 |
| BMI (kg/m²) | Median: 23.4 (21.6–25.4) | Mean: 24.2 ± 2.8 | Mean: 26.7 ± 7.5 | 15–24 (37.0%) | 25–29 (40.4%) |
| History of DM | 2.7%/2.7% | NA, excluded from controls | NA, excluded from controls | NA, excluded from controls | NA, excluded from controls |
| History of HTN | 16.6%/16.6% | 0%, excluded from controls | NA, matching with SBP | 1.8%, excluded from controls | NA, excluded from controls |
| Systolic blood pressure (mmHg) | Median: 120 (110–130) | Mean: 123.3 ± 10.0 | Mean: 121.0 ± 16.3 | <120 (53.3%) | 120–139 (39.6%) |
| Matching variable | Age, sex, BMI, DM, HTN, eGFR, albuminuria, era | Age, sex, BP, smoking status | Age, sex, race, BP, educational background, BMI, smoking status | Age, sex, race/ethnicity, educational background, smoking status, BMI, SBP | Age, sex, BMI, eGFR, albuminuria, HTN, DM, era |
| All-cause mortality incidence proportion (n), in donors/controls | 1.4% (24)/0.7% (12) | 11.8% (224)/7.4% (2,425) | NA | 3.1 per 10,000 donors/0.4 per 10,000 controls within 3 mo | 4.0% (52)/3.2% (1,072) |
| ESKD incidence proportion (n), in donors/controls | 0% (0)/0% (0) | 0.47% (9)/0.06% (22) | 0.10% (99)/0.04% (36) | NA | NA |
| Follow-up (yr) | Median: 7.65 (4.15–11.13) | Median: 15.1 (1.5–43.9) | Median: 7.6 (maximum: 15.0) | Median: 6.3 (3.2–9.8) | Mean: 12.3 ± 8.1 |

BMI, body mass index; BP, blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; HTN, hypertension; HUNT, Health Study of Nord-Trøndelag; NA, not applicable; NHANES III, the third National Health and Nutritional Examination Survey; SBP, systolic BP.
underlying disease, diabetes, donor age, and willingness to transplant of donors. Second, the absolute number of deaths was small because the donors were healthy individuals. However, this reflects the small absolute risk of adverse outcomes in living donors in South Korea. Additionally, the exact cause of death was unknown in this population, and the mortality events of living donors might not be associated with the donation itself. Moreover, donor data have been collected in electronic medical records since the 1980s, and the linked data from NHIS were established in 2003. Therefore, patients who had a clinical outcome before 2003 could not be detected. Last, the limited follow-up duration due to unavailability of data prevented us from investigating the long-term prognosis of living donors.

In conclusion, the risk of all-cause mortality was comparable between live kidney donors and matched non-donor healthy controls with similar health status in an Asian population after consideration of several clinicodemographic characteristics. Considering the relatively low absolute risk of mortality or ESKD, live kidney donation should not be discouraged. However, potential donors should be informed of the long-term risks, and only those who accept the risks should undergo donor nephrectomy. The present study adds to the evidence regarding medical considerations in live kidney donation. Additional long-term studies including larger numbers of donors and non-donor controls are needed to determine the risks of live kidney donation, including ESKD.

Conflicts of interest

All authors have no conflicts of interest to declare.

Funding

This study was supported by the National Evidence Collaborating Agency (project number NECA-A-20-005). The funder had no role in performing the study, and the study was independently performed by the authors.

Authors’ contributions

Conceptualization: EK, SP, HL
Investigation: EK, YK, HJK, MH, JHC, JPL, SL, SWK, SMP, DWC, HJC, YSK, YCK, IC, HL
Formal analysis: EK, SP, JP, MP, KK
Funding acquisition: HL
Writing–original draft: EK, SP
Writing–review & editing: HL
All authors read and approved the final manuscript.

ORCID

Eunjeong Kang, https://orcid.org/0000-0002-2191-2784
Sehoon Park, https://orcid.org/0000-0002-4221-2453
Jina Park, https://orcid.org/0000-0002-7410-1985
Yaerim Kim, https://orcid.org/0000-0003-1596-1528
Minsu Park, https://orcid.org/0000-0002-0624-5215
Kwangsoo Kim, https://orcid.org/0000-0002-4586-5062
Hyo Jeong Kim, https://orcid.org/0000-0002-5618-0042
Miyeun Han, https://orcid.org/0000-0001-7304-2496
Jang-Hee Cho, https://orcid.org/0000-0002-7031-5214
References

1. Mjoen G, Hallan S, Hartmann A, et al. Long-term risks for kidney donors. *Kidney Int* 2014;86:162–167.
2. Segev DL, Muzaale AD, Caffo BS, et al. Perioperative mortality and long-term survival following live kidney donation. *JAMA* 2010;303:959–966.
3. Garg AX, Meirambahyea A, Huang A, et al. Cardiovascular disease in kidney donors: matched cohort study. *BMJ* 2012;344:e1203.
4. Kim Y, Yu MY, Yoo KD, et al. Long-term mortality risks among living kidney donors in Korea. *Am J Kidney Dis* 2020;75:919–925.
5. O’Keeffe LM, Ramond A, Cherqaoui Z, et al. Very long-term follow-up of 1022 consecutive living donor nephrectomies: a systematic review and meta-analysis. *Ann Intern Med* 2018;168:276–284.
6. Muzaale AD, Massie AB, Wang MC, et al. Risk of end-stage renal disease following live kidney donation. *JAMA* 2014;311:579–586.
7. Maggiore U, Budde K, Heemann U, et al. Long-term risks of kidney living donation: review and position paper by the ERA-EDTA DESCARTES working group. *Nephrol Dial Transplant* 2017;32:216–223.
8. Muzaale AD, Massie AB, Segev DL. Concerns about the long-term safety of live kidney donors are justified. *Eur J Epidemiol* 2017;32:91–93.
9. Mjoen G, Øyen O, Holdaas H, Midtvedt K, Line PD. Morbidity and mortality in 1022 consecutive living donor nephrectomies: benefits of a living donor registry. *Transplantation* 2009;88:1273–1279.
10. Fehrman-Ekholm I, Elinder CG, Stenbeck M, Tydén G, Groth CG. Kidney donors live longer. *Transplantation* 1997;64:976–978.
11. Fournier C, Pallet N, Cherqaoui Z, et al. Very long-term follow-up of living kidney donors. *Transpl Int* 2012;25:385–390.
12. Kido R, Shibagaki Y, Iwadoh K, et al. How do living kidney donors develop end-stage renal disease? *Am J Transplant* 2009;9:2514–2519.
13. Williams SL, Oler J, Jorkasky DK. Long-term renal function in kidney donors: a comparison of donors and their siblings. *Ann Intern Med* 1986;105:1–8.
14. Najarian JS, Chavers BM, McHugh LE, Matas AJ. 20 years or more of follow-up of living kidney donors. *Lancet* 1992;340:807–810.
15. Clemens K, Boudville N, Dew MA, et al. The long-term quality of life of living kidney donors: a multicenter cohort study. *Am J Transplant* 2011;11:463–469.
16. Young A, Hodsmans AB, Boudville N, et al. Bone and mineral metabolism and fibroblast growth factor 23 levels after kidney donation. *Am J Kidney Dis* 2012;59:761–769.
17. Connor SL, Connor WE, Henry H, Sexton G, Keenan EI. The effects of familial relationships, age, body weight, and diet on blood pressure and the 24 hour urinary excretion of sodium, potassium, and creatinine in men, women, and children of randomly selected families. *Circulation* 1984;70:76–85.
18. Lee H, Oh SW, Heo NJ, et al. Serum phosphorus as a predictor of low-grade albuminuria in a general population without evidence of chronic kidney disease. *Nephrol Dial Transplant* 2012;27:2799–2806.
19. Yoo KD, Kang S, Choi Y, et al. Sex, age, and the association of serum phosphorus with all-cause mortality in adults with normal kidney function. *Am J Kidney Dis* 2016;67:79–88.
20. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009;150:604–612.
21. Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. *Am J Kidney Dis* 2010;55:622–627.
22. Seo MH, Lee WY, Kim SS, et al. 2018 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea. *J Obes Metab Syndr* 2019;28:40–45.
23. Garg AX, Prasad GV, Thiessen-Philbrook HR, et al. Cardiovascular disease and hypertension risk in living kidney donors: an analysis of health administrative data in Ontario, Canada. *Transplantation* 2008;86:399–406.
24. Janki S, Dehghan A, van de Wetering J, et al. Long-term prognosis after kidney donation: a propensity score matched comparison of living donors and non-donors from two population cohorts. *Eur J Epidemiol* 2020;35:699–707.
25. World Health Organization (WHO). International report on organ donation and transplantation activities executive summary [Internet]. Geneva: WHO; 2017 [cited 2021 Feb 21].
Available from: http://www.transplant-observatory.org/download/2017-activity-data-report/.

26. Wang L, Southerland J, Wang K, et al. Ethnic differences in risk factors for obesity among adults in California, the United States. *J Obes* 2017;2017:2427483.

27. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. *Diabetes Res Clin Pract* 2011;94:311–321.

28. Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insured population. *JAMA* 2002;287:2519–2527.

29. Pillay-van Wyk V, Bradshaw D. Mortality and socioeconomic status: the vicious cycle between poverty and ill health. *Lancet Glob Health* 2017;5:e851–e852.

30. Breeze E, Sloggett A, Fletcher A. Socioeconomic and demographic predictors of mortality and institutional residence among middle aged and older people: results from the Longitudinal Study. *J Epidemiol Community Health* 1999;53:765–774.

31. Tao S, Zeng X, Liu J, Fu P. Socioeconomic status and mortality among dialysis patients: a systematic review and meta-analysis. *Int Urol Nephrol* 2019;51:509–518.

32. Meijer M, Kejs AM, Stock C, Bloomfield K, Ejsstrud B, Schlattmann P. Population density, socioeconomic environment and all-cause mortality: a multilevel survival analysis of 2.7 million individuals in Denmark. *Health Place* 2012;18:391–399.